Biotech Stocks: What Is Inside the Biotech Theme

The theme applies one test: is the core business discovering, developing or commercialising biology-based medicine? In practice that means biologic drugs, gene and cell therapies, RNA medicines, and the discovery platforms that generate them.

The phrase doing the work is biology-based. Plenty of companies sell medicine. A large diversified drugmaker with a chemistry-led portfolio, a consumer health division and a dividend is a different business with a different risk profile, and admitting it would quietly turn the theme into a healthcare sector fund. That is the failure mode of most thematic screens in this space, because the sector boundary between biotech and pharma has genuinely blurred and the easy move is to stop enforcing it.

The second structural choice is the one that makes this theme unusual. Most themes layer by what a company does. This one layers by how far along the commercialisation path it is, because in biotech the business model, not the sector, is the risk. A company with an approved product and cash flow does not behave like a company whose value is a probability-weighted bet on a trial that reads out next year, even when they are working on the same disease with the same technology. Group by therapeutic area and you hide the only variable that reliably predicts how a holding will behave. For the general idea, see thematic investing.

These are the companies that already won. They have approved medicines selling at scale, the profits to fund the next decade of research without asking the market for money, and enough separate products that no single trial decides the outcome. In biotech that combination is rare and it is what makes this layer behave like an ordinary equity holding rather than a wager. The share price still moves on data, but it moves on a portfolio of data, and the balance sheet absorbs a failure instead of being ended by one.

How this layer relates to the rest. This layer is the theme's ballast, and it is also the buyer of last resort for everything below it. Large caps face patent expiry on their biggest products, and the standard response is to acquire a smaller company that already has an approved drug or a late-stage asset. That is the mechanism that ties the layers together economically rather than just listing them next to each other.

Halfway down the commercialisation ladder sits the most misread part of biotech. These companies have cleared the hard part: something is approved, it is selling, and there is revenue rather than a promise. What they have not cleared is concentration. One product, sometimes two, produces most of the revenue, so an expiry, a competitor entering the same indication, or a reimbursement decision does not trim earnings, it removes the thesis. They are less binary than a pipeline name and far more concentrated than a large cap, and that middle position is a genuinely different risk, not a blend of the two either side of it.

How this layer relates to the rest. This layer is where the patent cliff above meets the science below. A mid cap with one approved drug and an expiry in sight is precisely what a large cap acquires, and a pipeline name that succeeds becomes one of these before it becomes anything larger. Neurocrine Biosciences (NBIX), built around a movement-disorder medicine with a newer endocrine approval behind it, and BioMarin Pharmaceutical (BMRN), built around therapies for rare genetic diseases, are two further examples of the same shape.

At the top of the risk ladder are companies whose market value rests mostly on medicines that are not yet approved, or not yet selling at scale. Whatever revenue exists is not what the price reflects. What the price reflects is the market's running estimate of whether a set of programs will read out positive, clear a regulator, and find a payer, and that estimate updates in discrete jumps rather than continuously. This is the part of the theme that is binary in a way almost nothing else in the market is: a single trial readout can permanently reprice a company overnight, in either direction, and there is no operational response available afterwards.

How this layer relates to the rest. This layer is where the theme's optionality lives, and it is the layer the commercial layer eventually shops in. It depends on capital markets rather than on customers, so it is unusually sensitive to interest rates and risk appetite, which is why it can fall hard in a year when nothing scientific went wrong at all.

Every company above buys the same things: sequencers and reagents, laboratory instruments, contract research to run the trials, and contract manufacturing to make biological material at scale. The companies that sell those things occupy the one layer of the biotech economy that is indifferent to which drug succeeds. A failed Phase 3 is a catastrophe for the sponsor and a completed contract for the organisation that ran it. Revenue tracks how much research is being funded across the whole field, not whether any particular molecule hits its endpoint, which makes this the only part of the theme with no binary event risk of its own.

How this layer relates to the rest. It is worth stating plainly that this roster holds no name in this layer. That is a deliberate boundary rather than an oversight: the theme is drawn around companies discovering and commercialising therapies, and the large tools and instrument companies are diversified life-science equipment businesses whose revenue reaches well beyond biotech. The trade-off is real and worth knowing. Excluding the layer keeps the theme pure, and it also means the theme has no holding that benefits from research activity in general. The exposure this roster gives you is to specific molecules, all the way down.

Read as a ladder, the theme is a single company at four ages. A pipeline name that succeeds becomes a single-franchise mid cap. A mid cap that keeps succeeding, or that gets bought, becomes part of the commercial layer. And a commercial name whose biggest product runs out of patent life goes shopping in the layers below it. That is not a metaphor, it is the actual capital cycle of the sector, and it is why these twelve names are economically linked rather than merely co-listed.

The patent cliff is the clock that drives it. A protected medicine earns high margins, and when protection ends, revenue falls sharply rather than gradually. Every large cap therefore has a dated hole in its future earnings and a strong incentive to fill it by acquiring something already approved or close to it. That is the bid underneath the mid caps. It also means a mid cap can reprice for a reason that has nothing to do with its own trial calendar, which is one of the few pieces of genuinely good news in an otherwise punishing risk profile.

The practical consequence is that the twelve names do not move for one reason. A failed readout devastates a pipeline name and barely registers at Amgen. A pricing-policy shift hits the biggest sellers hardest and leaves a pre-revenue developer untouched. A rise in interest rates hurts the pipeline layer, which is funded by capital markets rather than customers, in a year when nothing scientific went wrong at all. Understanding which layer you own is more useful than any ranking of the twelve.

The gap in that chain is the layer this roster does not hold. Tools, instruments, contract research and contract manufacturing sell to every company above and get paid whether the drug works or not. It is the only part of the biotech economy without binary event risk of its own, and it is excluded here because the theme is drawn around companies developing therapies. Knowing what that boundary costs you is part of owning the theme deliberately.

A membership test is only credible if it excludes things. These are the names people most often expect to find here, and the specific reason each one does not qualify.

• Eli Lilly and Novo Nordisk. The two companies behind the GLP-1 medicines for diabetes and obesity. They are large, diversified drugmakers, and the reason anyone wants them is a drug class rather than a research platform, so the exposure belongs to a theme drawn around that class instead of one drawn around biology-driven discovery.
• Pfizer, Merck, Johnson & Johnson and AbbVie. Diversified pharmaceutical companies with broad approved-product bases, chemistry-led as well as biologics-led portfolios, and in some cases whole businesses outside medicine. They sit at the mature end of drug development where dividends and patent calendars drive the story, which is a different investment than the one this theme describes.
• Intellia and Beam Therapeutics. Gene-editing developers whose programs are earlier and largely pre-revenue. The biotech theme holds one editing name, and it holds the one with an approved partnered therapy. Owning the wider editing bench is a more concentrated and more binary thesis than this theme is built to express.
• Life-science tools and instrument companies. Sequencing, instruments, reagents and laboratory equipment are sold to biotech rather than developed by it, and the largest of these companies serve academic, industrial and diagnostic customers well beyond drug development. They fail a test that asks whether the company is discovering or commercialising a therapy, even though they are the layer least exposed to any single trial outcome.
• Contract research and manufacturing organisations. The businesses that run trials and manufacture biologics for other companies earn fees per study and per batch. Their revenue follows how much research is being funded across the sector, which is genuinely useful exposure, but it is exposure to biotech activity rather than to biotech outcomes.

Three of those exclusions have a home elsewhere. Lilly and Novo Nordisk anchor the GLP-1 and obesity drugs theme, where a specific drug class is the thesis rather than a side effect. The diversified drugmakers belong to the pharmaceutical stocks theme, where patent calendars, dividends and approved-product breadth are the point. And the wider editing field sits in the gene editing theme, which holds several pre-revenue editors together. This theme holds one of them, CRISPR Therapeutics, because it has crossed into having an approved partnered therapy. A company can be an excellent business and still be the wrong expression of a given theme.

The same 12 names, grouped by the stage of commercialisation they occupy rather than ranked, so the shape of the theme is visible at a glance.

Five sit in the commercial layer, five in the single-franchise layer, and two in the pipeline layer, with 10 of them covered in full above. That balance is the theme's central design decision. Tilt it toward the commercial layer and you own a slower, cash-generative version of the theme. Tilt it toward the pipeline layer and you own something closer to a set of binary bets.

The passive route is a biotech fund, and the choice between the two main ones is more consequential here than in most sectors. IBB is cap-weighted, so it leans heavily toward the large commercial names and gives you the steadier end of the theme by default. XBI is equal-weighted, which hands small and clinical-stage companies far more influence and makes it considerably more volatile. ARKG is actively managed around genomics for a narrower, higher-conviction slice. In most sectors that is a size-factor decision. In biotech it decides which layer you actually own, and the layers have different risk profiles rather than different degrees of the same risk.

A theme inverts the trade. You know exactly which twelve names you hold, which stage each one occupies, and what weight each carries, and you accept that twelve names is a narrower roster than a fund holds. Neither is automatically better. The fund is the simpler instrument, the theme is the more deliberate one, and plenty of people hold a broad fund as a core with a small thematic tilt beside it. For the fund route in detail, see best biotech ETFs.

A list of twelve names is an input, not a portfolio. What turns one into the other is structure: which layers you want exposure to, what weight each name carries, and whether the concentration you end up with was chosen or inherited.

• Decide the layer mix first, then the names. The split between commercial names and pipeline names changes the character of the position far more than swapping one oncology mid cap for another.
• Set target weights that sum to 100. Equal weighting across twelve names is a choice, and so is anchoring in the commercial layer with a small pipeline sleeve. Both are defensible. Not deciding is what leaves you concentrated by accident after one readout.
• Size the binary names before you buy. For a holding that can permanently reprice on one trial result, position size does more work than analysis does. Set it while you are calm rather than after a data headline.
• Frame it against the S&P 500. A narrow thematic position should be judged against a broad benchmark, because the extra concentration has to be buying you something.
• Revisit as weights move. Thematic positions drift fast when the constituents have this much dispersion between them, and biotech dispersion arrives in single days rather than over quarters.

This is what Walnut is built for. You describe the thesis, the AI assistant proposes constituents and weights you can edit, the portfolio tracks as one performance line against the S&P 500, and you place trades you approve yourself at your own broker. Walnut is informational and does not tell you which stocks to buy.

For the companion view of which biotech names are most widely held and discussed, see best biotech stocks. For the broader sector these companies sit inside, see best healthcare stocks.

The biotech theme is twelve companies across three occupied stages of commercialisation, and the staging is the whole idea. Vertex, Regeneron, Gilead, Amgen and Biogen have approved medicines and the cash flow to fund the next decade. Alnylam, Incyte, argenx, Neurocrine and BioMarin have cleared approval but carry an entire thesis in one or two products. Moderna and CRISPR Therapeutics are priced on programs that have not arrived, which makes them binary in a way almost nothing else in the market is. The fourth layer, the tools and services businesses that get paid whichever drug works, is described here and deliberately not held.

Understood as a flat list of twelve biotech stocks, the theme looks like a concentrated bet on drug innovation. Understood as a ladder with a patent cliff at the top pulling acquisitions up from below, it is a structure, and the structure is what you are deciding whether to own. Nothing here is a recommendation, and Walnut is not an investment adviser.